5. In a randomized controlled trial conducted to evaluate the efficacy and safety of dopamine (DA) and norepinephrine (NE) as the initial vasopressor in septic shock, 134 and 118 septic shock patients underwent DA or NE therapy, respectively. The primary efficacy end point was all-cause 28-day mortality. The results are summarized in Table 6.6.

(a) Estimate the 95% CIs of the 28-day mortality rate following DA and NE therapy.

(b) Estimate the 95% CI of the 28-day mortality rate difference between DA and NE therapy.